Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI(TM)-100 Advancing it Closer to First-in-Human Trials
Stock Information for Aditxt Inc.
Loading
Please wait while we load your information from QuoteMedia.